Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$91.26M+88.1%$84.22M+102%$64.17M+79.1%$55.86M+90.3%$48.52M+90.6%
$29.38M+2.8%$30.23M+13.6%$31.53M+35.3%$30.77M+47.9%$28.58M+40.9%
$120.63M+19.2%$114.45M+23.9%$119.79M+103%$110.72M+121%$101.18M+121%
-$120.01M-20.4%-$113.56M-25.0%-$118.72M-106%-$109.49M-125%-$99.71M-126%
$7.57M-41.4%$9.14M-12.6%$10.31M+32.6%$11.93M+169%$12.93M+680%
-$104.43M-29.8%-$108.41M-118%-$97.56M-120%-$86.78M-104%
-$111.13M-30.5%-$103.12M-30.1%-$105.8M-65.9%-$94.95M-60.9%-$85.17M-45.8%
-$1.40-12.0%-$1.40-12.0%-$1.50+3.2%-$1.36+20.5%-$1.25+35.2%
-$116.37M-19.9%-$110.31M-24.5%-$115.77M-108%-$106.65M-126%-$97.03M-125%
-$120.01M-20.4%-$113.56M-25.0%-$118.72M-106%-$109.49M-125%-$99.71M-126%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Perspective Therapeutics's revenue?
Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
Is Perspective Therapeutics profitable?
Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
What are Perspective Therapeutics's profit margins?
Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
What is Perspective Therapeutics's earnings per share?
Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
Where does Perspective Therapeutics's income statement data come from?
Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.